

1 The trustworthiness and impact of trial preprints for COVID-19

2 decision-making: A methodological study

3 Dena Zeraatkar

4 Department of Biomedical Informatics, Harvard Medical School

5 Department of Health Research Methods, Evidence, and Impact, McMaster University

6 Tyler Pitre

7 Department of Internal Medicine, McMaster University

8 Gareth Leung

9 Faculty of Medicine, University of Ottawa

10 Ellen Cusano

11 Cumming School of Medicine, University of Calgary

12 Arnav Agarwal

13 Department of Medicine, McMaster University

14 Faran Khalid

15 Department of Medicine, McMaster University

16 Zaira Escamilla

17 Department of Health Research Methods, Evidence, and Impact, McMaster University

18 Matthew Cooper

19 Department of Medicine, University of Alberta

20 Maryam Ghadimi

21 Department of Health Research Methods, Evidence, and Impact, McMaster University

22 Ying Wang

23 Department of Health Research Methods, Evidence, and Impact, McMaster University

24 Francisca Verdugo

25 Epistemonikos Foundation, Santiago, Chile

26 Gabriel Rada

27 Epistemonikos Foundation, Santiago, Chile

28 Elena Kum

29 Department of Health Research Methods, Evidence, and Impact, McMaster University

30 Anila Qasim

31 Department of Health Research Methods, Evidence, and Impact, McMaster University

32 Jessica J Bartoszko

33 Department of Health Research Methods, Evidence, and Impact, McMaster University

34 Reed Siemieniuk

35 Department of Health Research Methods, Evidence, and Impact, McMaster University

36 Chirag J. Patel

37 Department of Biomedical Informatics, Harvard Medical School

38 Gordon Guyatt

39 Department of Health Research Methods, Evidence, and Impact, McMaster University

40 Romina Brignardello-Petersen

41 Department of Health Research Methods, Evidence, and Impact, McMaster University

42

43 **Running head:** trustworthiness and impact of COVID-19 trial preprints

44 **Disclaimers:** None.

45 **Funding:** This study was supported by the Canadian Institutes of Health Research CIHR-IRSC:057900132
46 and Coronavirus Rapid Research Funding Opportunity - OV2170359. DZ is funded by a Banting
47 Postdoctoral Fellowship.

48 **Competing interests:** None

49 **Data:** Data is available at <https://osf.io/9adxb/>.

50 **Acknowledgements:** None.

51 **Authors' Contributions:** DZ, RS, and RBP conceptualized the study. JJB, FV, GR, and AQ screened studies
52 for eligibility. TP, GL, EC, AA, FK, ZE, MC, MG, YW, EK, JJB, and AQ collected data. DZ drafted the first
53 version of the manuscript. All authors reviewed the manuscript and provided important intellectual
54 input.

55 **Word count:** 5,240

56

57

58 **Abstract**

59

60 **Purpose:** To assess the trustworthiness and impact of preprint trial reports during the COVID-19
61 pandemic.

62 **Data sources:** WHO COVID-19 database and the L-OVE COVID-19 platform by the Epistemonikos
63 Foundation (up to August 3rd, 2021)

64 **Design:** We compare the characteristics of COVID-19 trials with and without preprints, estimate time to
65 publication of COVID-19 preprint reports, describe discrepancies in key methods and results between
66 preprint and published trial reports, report the number of retracted preprints and publications, and
67 assess whether including versus excluding preprint reports affects meta-analytic estimates and the
68 certainty of evidence. For the effects of eight therapies on mortality and mechanical ventilation, we
69 performed meta-analyses including preprints and excluding preprints at 1 month, 3 months, and 6
70 months after the first trial addressing the therapy became available either as a preprint or publication
71 (120 meta-analyses in total).

72 **Results:** We included 356 trials, 101 of which are only available as preprints, 181 as journal publications,
73 and 74 as preprints first and subsequently published in journals. Half of all preprints remain unpublished
74 at six months and a third at one year. There were few important differences in key methods and results
75 between trial preprints and their subsequent published reports. We identified four retracted trials, three
76 of which were published in peer-reviewed journals. With two exceptions (2/60; 3.3%), point estimates
77 were consistent between meta-analyses including versus excluding preprints as to whether they
78 indicated benefit, no appreciable effect, or harm. There were nine comparisons (9/60; 15%) for which
79 the rating of the certainty of evidence differed when preprints were included versus excluded, for four
80 of these comparisons the certainty of evidence including preprints was higher and for five of these
81 comparisons the certainty of evidence including preprints was lower.

82 **Limitations:** The generalizability of our results is limited to COVID-19. Preprints that are subsequently
83 published in journals may be the most rigorous and may not represent all trial preprints.

84 **Conclusion:** We found no compelling evidence that preprints provide less trustworthy results than
85 published papers. We show that preprints remain the only source of findings of many trials for several
86 months, a length of time that is unacceptable in a health emergency. We show that including preprints
87 may affect the results of meta-analyses and the certainty of evidence. We encourage evidence users to

88 consider data from preprints in contexts in which decisions are being made rapidly and evidence is being
89 produced faster than can be peer-reviewed.

90

Summary Box 1

What is already known on this topic

- Clinicians and decision-makers need rapidly available and credible data addressing the comparative effectiveness of treatments and prophylaxis for COVID-19.
- Investigators have adopted preprint servers, which allow the rapid dissemination of research findings before publication in peer-reviewed journals.

What this study adds

- We found no compelling evidence that preprints provide less trustworthy results than published papers.
- We show that including preprints may affect the results of meta-analyses and the certainty of evidence and we encourage evidence users to consider data from preprints in contexts in which decisions are being made rapidly and evidence is being produced faster than can be peer-reviewed.

91

92 **Background**

93 During the COVID-19 pandemic, the scientific community adopted preprint servers, which allow
94 investigators to disseminate research findings before publication in peer-reviewed journals. Authors of
95 seminal COVID-19 trials, for example, representing massive international collaborations, such as
96 RECOVERY (1-4) and SOLIDARITY (5, 6), reported their results in preprints before subsequent publication
97 in journals.

98 Growing interest in preprints predates the COVID-19 pandemic (7, 8). Researchers and evidence users
99 have raised concerns that the traditional publication model is slow, peer review may not always improve
100 the quality of manuscripts, journals impede dissemination due to paywalls and high publication fees and
101 encourage publication bias by prioritizing statistically significant or anomalous findings—issues preprints
102 may avoid (9-15). Despite these concerns, and the potential of preprints to address them, because
103 preprints may result in the dissemination of provisional findings that contain important errors that,
104 presumably, published papers do not, the medical community has been cautious regarding their
105 adoption (16, 17).

106 Authors of systematic reviews, guideline developers, and other decision makers face a trade-off when
107 considering preprints: on the one hand, including preprints could reduce the credibility of evidence
108 syntheses and risk serious errors if important differences appear in published reports; on the other,
109 including preprints may increase the precision of estimates; allow timely dissemination of research, and
110 may minimize the effects of publication bias.

111 Knowledge of the extent to which preprints may accelerate the dissemination of findings, the frequency
112 and nature of discrepancies between pre-prints and subsequent published reports, frequency of
113 retractions of preprints compared to publications, and the impact preprints on meta-analytic estimates
114 could inform the trade-off that evidence users face. Our study capitalizes on our living systematic
115 reviews and network meta-analyses (SRNMAs) of drug treatments, antiviral antibodies and cellular
116 therapies, and prophylaxis for COVID-19—an initiative launched in July 2020 that provides real-time
117 summaries addressing the comparative effectiveness of treatments and prophylaxis for COVID-19—to
118 report on the characteristics, trustworthiness—that is, complete and consistent reporting of key aspects
119 of the methods and results between preprint and published trial reports—and impact of COVID-19 trial
120 preprint reports (18-20).

121 **Methods**

122 We submitted a protocol for this study for publication on September 7th, 2021. Because the protocol
123 was still under review at the time the study was completed, we withdrew the protocol for publication
124 and present it in Supplement 1.

125 **Search**

126 Our study uses the search strategy of our living SRNMA that includes daily searches in the World Health
127 Organization (WHO) COVID-19 database—a comprehensive multilingual source of global published and
128 preprint literature on COVID-19 (<https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/>). Prior to its merge with the WHO COVID-19 database on 9 October 2020, we searched the
129 US Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable
130 Database. A validated machine learning model facilitates efficient identification of randomized trials
131 (21).
132

133 Our search is supplemented by ongoing surveillance of living evidence retrieval services, including the
134 Living Overview of the Evidence (L-OVE) COVID-19 platform by the Epistemonikos Foundation
135 (<https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d>) and the Systematic and Living Map
136 on COVID-19 Evidence by the Norwegian Institute of Public Health
137 (<https://www.fhi.no/en/qk/systematic-reviews-hta/map/>). Using the above sources, we also monitor for
138 retraction notices and concerns regarding trial integrity. Supplement 2 includes additional details of our
139 search strategy.

140 **Study selection**

141 As part of the living SRNMA, pairs of reviewers, following calibration exercises to ensure sufficient
142 agreement, work independently and in duplicate to screen titles and abstracts of search records and
143 subsequently the full texts of records determined potentially eligible at the title and abstract screening
144 stage. Reviewers also link preprint reports with their subsequent publications based on trial registration
145 numbers, the names of investigators, recruiting centres and countries, dates of recruitment, and other
146 trial characteristics. When links between preprints and subsequent publications are unclear, we contact
147 the author for confirmation. Reviewers resolve discrepancies by discussion or, when necessary, by
148 adjudication with a third-party reviewer.

149 Eligible preprint and peer reviewed articles report trials that randomize patients with suspected,
150 probable, or confirmed COVID-19 to drug treatments, antiviral antibodies and cellular therapies,
151 placebo, or standard care or trials that randomize healthy participants exposed or unexposed to COVID-

152 19 to prophylactic drugs, standard care, or placebo. We do not apply any restrictions on severity of
153 illness, setting, or language of publication but do exclude trials that report on nutritional interventions,
154 traditional Chinese herbal medicines without standardization in formulations and dosing across batches,
155 and non-drug supportive care interventions.

156 We did not perform a sample size calculation since we included all eligible trial reports identified
157 through our living SRNMA up to August 3rd, 2021.

158 ***Data collection***

159 As part of the living SRNMA, for each eligible trial, pairs of reviewers, following training and calibration
160 exercises, independently extract trial characteristics, methods, and results using a standardized, pilot
161 tested data extraction form. To assess risk of bias, reviewers, following training and calibration
162 exercises, use a revision of the Cochrane tool for assessing risk of bias in randomized trials (RoB 2.0) (22)
163 (Supplement 3). Reviewers resolve discrepancies by discussion and, when necessary, by adjudication
164 with a third party.

165 For the current study, pairs of trained and calibrated reviewers, working independently and in duplicate
166 and using a pilot-tested form, collected data on differences in key methods and results between
167 preprint and published trial reports. Key methods included description of the randomization process and
168 allocation concealment, blinding of patients and healthcare providers, extent of and handling of missing
169 outcome data, blinding of outcome assessors and adjudicators, and prespecification of outcomes and
170 analyses. Key results included number of participants analyzed and number of events in each trial arm
171 for dichotomous outcomes and number of participants analyzed, means or medians and measures of
172 variability for continuous outcomes. We focused on the same outcomes as our living SRNMA: mortality,
173 mechanical ventilation, adverse events leading to discontinuation, viral clearance, admission to hospital,
174 viral clearance, hospital length of stay, ICU length of stay, duration of mechanical ventilation, time to
175 symptom resolution or clinical improvement, time to viral clearance, days free from mechanical
176 ventilation, and time to viral clearance. For preprints with more than one version, we extracted data
177 from the first version of the preprint, which is the least likely to have been modified in response to peer
178 review.

179 Because risk of bias may vary across outcomes, for this analysis we present risk of bias judgements
180 corresponding to the following hierarchy of outcomes for therapy trials: mortality, mechanical
181 ventilation, duration of hospitalization, time to symptom resolution or clinical improvement, and
182 virologic outcomes. For prophylaxis trials, we used the following hierarchy: mortality, laboratory

183 confirmed and suspected COVID-19 infection, and laboratory confirmed COVID-19 infection. These
184 hierarchies represent the relative importance of outcomes based on rankings made by the linked WHO
185 guideline panel (23).

186 ***Data synthesis and analysis***

187 *Characteristics and risk of bias of trials*

188 We compare the characteristics and risk of bias of trials with preprints, trials with publications, and trials
189 first posted as a preprint and subsequently published by calculating differences in proportions and
190 associated confidence intervals.

191 *Time to publication of trial preprints*

192 We calculated the median time from a trial being posted on a preprint server to its eventual publication
193 in a journal and used Kaplan-Meier curves and log-rank tests to assess whether source of funding,
194 number of centers and participants, early termination for benefit, intensity of care (inpatient versus
195 outpatient), and severity (mild/moderate versus severe/critical COVID-19), statistically significant
196 primary or secondary outcomes (based on cut-offs defined by the authors or, when no cut-offs were
197 defined, based on a cut-off of $p < 0.05$ or confidence intervals not including the null), and risk of bias
198 (trials rated at low versus high risk of bias) are predictive of time to publication of trial preprints.

199 *Differences between preprint and published trial reports*

200 Among trial preprints that were subsequently published in a peer reviewed journal, we described the
201 number and types of discrepancies in key methods and results between preprint and published trial
202 reports. For discrepancies in the reporting of key methods, we report the number and percentage of the
203 changes between preprints and publications that affected risk of bias judgements—changes that we
204 considered to be critical.

205 *Retractions*

206 We compare the number of preprint and published trials that have been retracted.

207 *Comparison of meta-analyses including versus excluding evidence from preprints*

208 For trials that report on interventions that have been addressed by the linked WHO living guideline (23)
209 up to August 3rd 2021 (i.e., corticosteroids, remdesivir, lopinavir-ritonavir, hydroxychloroquine,
210 ivermectin, IL-6 receptor blockers, and convalescent plasma for treatment and hydroxychloroquine for
211 prophylaxis) and the two most commonly reported outcomes (i.e., mortality, mechanical ventilation),

212 we conducted pairwise frequentist random-effects meta-analyses with the restricted maximum
213 likelihood estimator including versus excluding evidence from preprints at one, three, and six months
214 after the first trial addressing the drug of interest was made public, either via preprint or publication.
215 We also conducted an analysis including versus excluding evidence from preprints at August 3rd—the
216 longest timepoint at which we collected data. For hydroxychloroquine for prophylaxis, because
217 mechanical ventilation was not an outcome of interest for prophylaxis trials, we report only on
218 mortality.

219 To facilitate interpretation, we calculated absolute effects. To calculate absolute effects, for drug
220 treatments, we used mortality data from the CDC and data on ventilation from the International Severe
221 Acute Respiratory and Emerging Infection COVID-19 database (24-26). For prophylaxis, we used the
222 event rate among all participants randomized to standard care or placebo to calculate the baseline risk.

223 We compared the direction of effect between meta-analyses including versus excluding preprints. We
224 considered the direction of effect different if one point estimate suggested no effect and another
225 suggested a benefit or harm or if one point estimate suggested benefit and another suggested harm. For
226 treatment, we considered an effect to be beneficial if the point estimate indicated a reduction in risk of
227 mortality of 1% or greater or a reduction in risk of mechanical ventilation of 2% or greater for treatment.
228 For prophylaxis, we considered an effect to be beneficial if the point estimate indicated a reduction in
229 risk of mortality of 0.5% or greater. For treatment, we considered an effect to be harmful if the point
230 estimate indicated that there was an increase in risk of mortality of 1% or greater or an increase in risk
231 of mechanical ventilation of 2% or greater. For prophylaxis, we considered an effect to be harmful if the
232 point estimate indicated an increase in risk of mortality of 0.5% or greater for prophylaxis. Otherwise,
233 we inferred that there was no important effect.

234 The GRADE approach provided the framework for assessing certainty of evidence and informed whether
235 including versus excluding preprint reports led to differences in ratings of the overall certainty of
236 evidence, judgments related to specific GRADE domains, and whether differences in ratings are likely to
237 impact decision making (i.e., evidence rated as high/moderate versus low/very low) (27). A minimally
238 contextualized approach informed ratings of imprecision (28). We considered any effect on mortality
239 and mechanical ventilation to be important. Thresholds of 1% risk difference for mortality and a 2% risk
240 difference for mechanical ventilation informed judgements of minimal or no treatment effect. For
241 prophylaxis and mortality, we used a 0.5% risk difference (28).

242 We performed all statistical analysis in R (version 4.03, R Foundation for Statistical Computing), using
243 the meta, forestplot, survival, and survminer packages.

244 ***Patient/Public Involvement***

245 Patients were involved in outcome selection, interpretation of results, and the generation of parallel
246 recommendations, as part of the parallel SRNMA and guidelines (23).

247 **Results**

248 ***Trial characteristics***

249 As of August 3rd, we identified 356 eligible trials, 101 of which were only available as preprints, 181 only
250 available as journal publications, and 74 first available as preprints and subsequently published as
251 journal articles. Supplement 4 presents additional details on the results of the search and Table 1
252 presents overall trial characteristics overall and trial characteristics stratified by publication status.

253 Typical trials were registered, completed at the time of reporting, addressed drug therapies, enrolled
254 less than 250 participants, reported one or more secondary outcomes that were statistically significant,
255 and were funded by governments and/or institutions. Nearly two thirds of trials were at high risk of bias,
256 primarily due to their open-label design.

257 Compared to published trials without preprints, trials only available as preprints and trials first available
258 as preprints and then subsequently published were more likely to be registered; trials only available as
259 preprints were more likely to report on interim results, describe drug therapies compared to antiviral
260 antibodies and cellular therapies or prophylaxis, and to have received industry funding; and trials first
261 posted as preprints and subsequently published were more likely to have received government funding.

262 ***Predictors of publication and time to publication***

263 During the 1.5 year span of this study, of 175 preprints, 74 (42.3%) were subsequently published in peer-
264 reviewed journals. Table 2 presents the proportion of preprints published up to one year and table 3
265 presents predictors of publication. A quarter of preprints were published in peer reviewed journals by 3
266 months after the preprint first became available and half by 6 months. At one year, a third of preprints
267 remained unpublished.

268 Preprints that received government funding, reported on inpatients, or reported on patients with severe
269 disease were published faster than preprints that did not receive government funding, reported on
270 outpatients, or patients with mild/moderate disease, respectively.

271 ***Differences between preprint and published trial reports***

272 Forty-two trials (56.8%) had one or more discrepancies in the reporting of key methods and results
273 between the preprint and the later published trial report. Supplement 5 describes these discrepancies.

274 Thirty trials (40.5%) had one or more discrepancies in the reporting of key methods--all of which had to
275 do with information either missing from the preprint or the publication. The most common discrepancy
276 in the reporting of key methods was the description of allocation concealment, which occurred in eight
277 trials. Box 1 presents an example. Our judgement of risk of bias for the randomization domain changed
278 from 'probably high risk of bias' to 'low risk of bias' for four of these eight trials due to additional details
279 reported in the published report.

Box 1: Example of a trial that reported additional information on allocation concealment in the published report

The PANAMO trial, which was initially available as a preprint on SSRN and later published in *Lancet Rheumatology*, provided additional details in the publication on allocation concealment. The publication describes central randomization with an online tool and the development of the randomization list by a third party—all of which were not reported in the preprint (29, 30).

Preprint

“Patients were randomly assigned in a 1:1 ratio to receive IFX-1, at a dose of 800 mg intravenously, for a maximum of seven doses, plus best supportive care, or best supportive care only. [...] Randomization was performed with an online tool within the eCRF [electronic case report form] and was stratified by study site.”

Publication

“Patients were randomly assigned in a 1:1 ratio to IFX-1 plus best supportive care (the IFX-1 group) or to best supportive care only (the control group). Randomisation was done by investigators centrally with an online tool within the electronic case report form and was stratified by study site. The tool used a randomised variable block length of either 2 or 4. The randomisation list was only available to contract research organisation (Metronomia) staff involved in the production of the randomisation list and set-up of the online randomisation tool.”

280

281 Other differences in the reporting of key methods were the publication reporting one or more additional
282 statistics important for meta-analysis (e.g., IQR or SD) that were not previously reported in the preprint
283 (n=6; 8.1%), the preprint reporting on interim results and the publication on completed trial results

284 (n=4; 5.4%), and the publication including a protocol and/or statistical analysis plan as a supplementary
285 that was not previously included with the preprint (n=3; 4.1%). The overall trial rating of risk of bias,
286 however, changed only for one trial based on additional information provided in the published report.

287 Thirty-one trials (41.9%) had one or more differences in the reporting of key results between preprints
288 and publications. The most common discrepancy in the reporting of key results were changes in
289 outcome data between preprints and publications, which was seen in 20 trials (27.0%)—though most of
290 these discrepancies may be attributed to events accumulating in trials from the time at which the
291 preprint was posted to when the trial was published. Box 2 presents an example.

Box 2: Example of a trial that reported different outcome data between the preprint and publication

The RECOVERY publication on dexamethasone, for example, reported different results for mortality and mechanical ventilation—likely not because of an error in the preprint but because of events accumulating in the trial from when the preprint was posted to when it was published (2, 31).

Outcome	Preprint (31)	Publication (2)
Mortality	Corticosteroids: 454/2104 (21.6 %) Standard care: 1065/4321 (24.6%)	Corticosteroids: 482/2104 (22.9%) Standard care: 1110/4321 (25.7%)
Mechanical ventilation	Corticosteroids: 92/1780 (5.2%) Standard care: 258/3638 (7.1%)	Corticosteroids: 110/1780 (6.2%) Standard care: 298/3638 (8.2%)

292
293 Despite discrepancies in outcome data being common, the magnitude and precision of effects were
294 similar between preprints and publications. Figure 1 shows differences in results on mortality and
295 mechanical ventilation between preprints and publications. Among all preprints with differences in
296 outcomes, differences in relative effects did not exceed 15%, except for one trial with very few events
297 that included just one additional event in the publication (32, 33). Other differences between preprints
298 and publications in key results included the publication reporting an outcome that was not included in
299 the preprint (n=11; 14.9%).

300 **Retractions**

301 We identified four retracted trials (34-41). Two trials reported on (hydroxy)chloroquine (34, 35)(36, 37),
302 two on favipiravir (36, 37)(38, 39), and two on ivermectin (34, 35)(40, 41). One of the four trials was
303 single-centre (40, 41) and the remainder were multi-centre trials. One of the trials was retracted when
304 the authors noticed an error in their analysis (40, 41) and the remainder were retracted due to concerns

305 about data fabrication or falsification (e.g., inconsistencies between the eligibility criteria and patients
306 included in the trial, discrepancies between when the trial was reported to have been conducted and
307 when patients were recruited, inconsistencies between the dataset and the results reported in the
308 preprint, inconsistencies between the distribution of baseline variables and the described randomization
309 procedure). We compared the number of retractions between preprints and journal publications. One of
310 the retracted trials was posted as a preprint (34, 35) and the remainder were published in peer-
311 reviewed journals.

312 ***Evidence synthesis including versus excluding preprint reports***

313 Table 4 presents results of meta-analyses including and excluding data from unpublished preprints for
314 the comparison of placebo or standard care with corticosteroids, remdesivir, lopinavir-ritonavir,
315 hydroxychloroquine, ivermectin, IL-6 receptor blockers, and convalescent plasma and mortality and
316 mechanical ventilation at 1 month, 3 months, and 6 months after the first trial addressing the
317 intervention was made public, either as a preprint or a publication, and at the longest point of follow-up
318 of the trials (August 3rd). In total, we performed and assessed the certainty of evidence of 120 meta-
319 analyses, 60 of which included preprints and 60 of which excluded preprints. Supplement 6 presents
320 forest plots for meta-analyses.

321 Because of insufficient data, we could not perform meta-analyses for six comparisons without preprints:
322 mortality and mechanical ventilation, at one month, for ivermectin vs. placebo/standard care and IL-6
323 receptor blockers vs. placebo/standard care and mortality and mechanical ventilation, at three months,
324 for ivermectin vs. placebo/standard care.

325 ***Differences in estimates from meta-analyses including versus excluding preprints***

326 Except for two cases, across all meta-analyses including and excluding results from unpublished
327 preprints, the point estimates were consistent as to whether they indicated benefit, no appreciable
328 effect, or harm. The meta-analysis of corticosteroids at one month suggested a reduction in risk of
329 mechanical ventilation when preprints were excluded (43 fewer per 1,000 people [95% CI 59.24 fewer to
330 22.12 fewer]; moderate certainty) and no appreciable effect when preprints were included (1.2 more
331 per 1,000 people [95% CI 60.3 fewer to 131.1 more]; very low certainty). The meta-analysis of
332 ivermectin at 6 months suggested no appreciable effect on risk of mechanical ventilation when preprints
333 were excluded (2.3 fewer per 1,000 people [95% CI 52.2 fewer to 83.5 more]; low certainty) and a
334 reduction in risk of mechanical ventilation (26.7 fewer per 1,000 people [95% CI 74.2 fewer to 75.4
335 more]; very low certainty) when preprints were included.

336 *Differences in ratings of the certainty of evidence from meta-analyses including versus excluding*
337 *preprints*

338 There were nine cases for which the rating of the certainty of evidence was different when preprints
339 were included versus excluded. For four of these nine cases, we rated the certainty of evidence
340 including preprints higher than the evidence excluding preprints due to no serious concerns in
341 imprecision in analyses including preprints. For five of these nine cases, we rated the certainty of
342 evidence excluding preprints higher than the evidence including preprints, due to serious imprecision for
343 four of five cases and due to serious imprecision and serious risk of bias for one of five cases. In six of
344 these cases, differences in ratings of the certainty of evidence may have impacted decision-making (i.e.,
345 evidence including preprints is rated as high/moderate whereas evidence excluding preprints is rated as
346 low/very low or vice versa).

347 *Differences in ratings of the GRADE risk of bias domain from meta-analyses including versus excluding*
348 *preprints*

349 Between meta-analyses including versus excluding preprints, judgements related to the GRADE risk of
350 bias domain differed only for the meta-analysis of remdesivir and mechanical ventilation at 6 months.
351 We rated the meta-analysis excluding preprints to not have any concerns related to risk of bias and
352 downgraded the meta-analysis including preprints due to serious risk of bias.

353 *Differences in ratings of the GRADE imprecision domain from meta-analyses including versus excluding*
354 *preprints*

355 Between meta-analyses including versus excluding preprints, judgements related to the GRADE
356 imprecision domain differed for 13 meta-analyses. We judged nine meta-analyses excluding preprints to
357 have more serious concerns related to imprecision than their counterparts including preprints (i.e.,
358 additional data from preprints narrowed confidence intervals) and we judged four meta-analyses
359 excluding preprints to have less serious concerns related to imprecision than their counterparts including
360 preprints (i.e., additional data from preprints increased statistical heterogeneity and hence imprecision).

361 **Discussion**

362 ***Main findings***

363 Our study presents a detailed assessment of the trustworthiness and impact of COVID-19 trial preprint
364 reports. We show that preprints remain the only source of findings of many trials for several months.
365 Half of all preprints, for example, remain unpublished at six months and a third at one year—a length of

366 time that may be unacceptable in a health emergency like COVID-19. Preprints can importantly
367 accelerate the time to dissemination of trial findings.

368 We did not find compelling evidence of important differences between preprint and published reports
369 of trials—though preprint reports of trials that are subsequently published in journals may not be
370 representative of all trial preprints. Further, we found retractions to occur for both preprints and
371 publications, suggesting that publication in a peer-reviewed journal alone does not indicate
372 trustworthiness of a trial report.

373 We also found that in most cases, meta-analyses including versus excluding evidence from preprints
374 yielded consistent results and the same certainty of evidence. In a minority of circumstances, however,
375 including preprints improved the certainty of evidence. At six months after trial data first became
376 available, when preprints were excluded, we found low certainty evidence that IL-6 receptor blockers
377 may reduce mortality—downgraded due to risk of bias and imprecision. Conversely, we found moderate
378 certainty evidence IL-6 receptor blockers probably reduce mortality when preprints were included—
379 downgraded due to risk of bias. For the case of IL-6 receptor blockers, considering evidence from
380 preprints may have importantly accelerated the time to incorporation of IL-6 receptor blockers as part
381 of standard care (23). In a minority of circumstances, including preprints also reduced the certainty of
382 evidence. At one month, for example, when preprints were excluded, we found moderate certainty
383 evidence that corticosteroids probably reduce mechanical ventilation—downgraded due to serious risk
384 of bias—and very low certainty evidence when we included preprints—downgraded due to serious risk
385 of bias and very serious imprecision. For the case of corticosteroids, including preprints increased
386 heterogeneity (and hence increased imprecision), and may have misinformed evidence users.

387 ***Implications***

388 Our findings have implications for evidence users who are concerned with the trustworthiness of
389 preprints and for systematic reviewers and guideline developers deciding whether to consider preprint
390 reports in systematic reviews and guideline recommendations. Our results support the overall
391 trustworthiness of preprints and preprints as a venue through which the dissemination of trial findings
392 may be accelerated. Peer review likely only addresses transparency of the trial reports and
393 interpretation of results because at the time of submission the trial has already been conducted and
394 major methodological decisions (such as whether to collect data on an outcome or whether to blind
395 investigators) cannot be changed. We encourage systematic reviewers and guideline developers to

396 consider trial evidence from preprints, especially in circumstances in which decisions are being made
397 rapidly and evidence is being produced faster than can be peer reviewed and published.

398 We caution, however, that preprints (and publications) may describe untrustworthy trials with
399 fabricated or falsified data. Evidence users may consider scrutinizing both preprint and published trials
400 for anomalies that may suggest fabrication and falsification (Examples of which are reported in Box 3)
401 (42, 43). While such methods cannot be used to definitively identify untrustworthy trials and require
402 subjective judgements, they may be useful to identify trials that are at high risk of such issues. Evidence
403 users may subsequently investigate such trials further or systematic reviewers may consider sensitivity
404 analyses excluding such trials from meta-analyses. We direct readers to other sources that describe
405 these methods (44).

Box 3: Methods to assess for fabrication and falsification in clinical trials (44)

1. Judge whether the reported recruitment speed is feasible given local disease patterns, trial eligibility criteria, and capacity of the recruiting centres (45, 46).
2. Review the trial registration or protocol and assess the consistency between the registration and the manuscript in aspects of the trial that cannot be modified after completion (e.g., blinding status).
3. Review profiles of investigators and/or institutions involved for a history of research misconduct.
4. Review baseline patient characteristics and test whether reported distributions are consistent with randomization (42, 43, 47).
5. Review primary data, when available, for duplicate records or inconsistencies between the data and reported statistics in the trial manuscript.
6. Review primary data, when available, and assess whether correlations between variables are plausible (45).

406

407 ***Relation to previous work***

408 Our study is the first to present data addressing the contribution of preprints to the body of evidence
409 addressing the comparative effectiveness of COVID-19 therapies and prophylaxis.

410 Two studies have reported on differences between preprint and published study reports and citations
411 and Altmetric attention metrics (48, 49). One study addressed publication characteristics and
412 dissemination of COVID-19 preprints and the other spin in interpretation of results. Both studies were,

413 however, restricted to only publications up to August and October 2020—which is not representative of
414 the current landscape of COVID-19 research and which does not include the majority of evidence being
415 currently used to guide COVID-19 care, including critical trials addressing the effects of corticosteroids
416 and IL-6 receptor blockers (1, 2). These studies did not compare the effects of including preprints on
417 meta-analytic estimates and the certainty of the body of evidence, which is particularly important
418 because evidence users use the totality of the body of evidence, rather than single studies, to make
419 treatment decisions and recommendations (48).

420 The COVID-19 pandemic highlighted the need for rapid dissemination of research and incited increased
421 interest in preprint servers, which yielded to an incredible amount of research that was published on
422 preprint servers and which made this study possible. We are not aware of studies addressing the
423 trustworthiness or impact of preprints in other areas—though such research in other areas would also
424 be useful.

425 ***Strengths and limitations***

426 The strengths of this study include the comprehensive search for, and inclusion of preprint and
427 published COVID-19 trial reports and rigorous data collection. The generalizability of our results is,
428 however, limited to COVID-19. Journals have expedited the publication of COVID-19 research and have
429 been publishing more prolifically on COVID-19 than in other areas, which may reduce opportunity for
430 revisions between preprints and their subsequent publications and may mean time to and predictors of
431 publication may be different than in other research areas.

432 Although the WHO COVID-19 database is a comprehensive source of published and preprint literature, it
433 does not include all preprint servers—though preprint servers not covered by our search address other
434 subjects and are unlikely to include COVID-19 trials.

435 It is likely that preprint reports of trials that are subsequently published in journals represent the most
436 rigorous or transparently reported preprints and that they are not representative of all trial preprints.

437 To assess preprint trustworthiness, we compared reporting of key aspects of the methods and results
438 between preprint and published trial reports. We acknowledge, however, that published trial reports
439 may still contain errors and that posting trial reports as preprints may allow more errors to be identified
440 prior to final publication.

441 We report on the number of publications and preprints that were retracted. Preprints, however, may be
442 less likely to be retracted because they may draw less attention and because preprint servers may be
443 less likely than journals to have formal policies addressing research integrity.

444 Our assessment of the contribution of trial preprint reports to meta-analytic estimates and their effect
445 on the certainty of evidence was undertaken in the context of pairwise meta-analysis and the minimally
446 contextualized approach for assessing the certainty of evidence whereas parallel guideline
447 recommendations have been based on network meta-analyses and the fully contextualized approach
448 (23, 28). There are no compelling reasons that our results will not be generalizable to network meta-
449 analyses. On the other hand, there will be more differences in judgements related to the certainty of
450 evidence in a fully contextualized framework where judgements are more dependent on the magnitude
451 and precision of estimates.

452 We limited our assessment of the impact of including versus excluding preprint reports on meta-analytic
453 estimates to only interventions that have been addressed by the WHO living guideline at the time of
454 analysis (23). While the effects of including or excluding preprints in meta-analyses may vary across
455 interventions, our analysis addresses the interventions for which there has been sufficient interest and
456 research to instigate guideline recommendations. Interventions informed by fewer trials may be more
457 sensitive to including or excluding evidence from preprints.

458 Our estimate of the time to publication of preprint reports may be overestimated if some preprint
459 authors do not attempt to subsequently publish in peer-reviewed journals—although evidence shows
460 that most authors of COVID-19 preprints intend to publish their findings (48). Time to publication may
461 also be underestimated if preprints are made public later in the submission process.

462 Finally, although we describe discrepancies in the reporting of key methods and results, we did not
463 assess differences in the discussion or conclusion sections of trial reports.

464 **Conclusions**

465 We found no compelling evidence that preprint trial reports provide less trustworthy results than
466 published trials. We show that including preprints may affect the results of meta-analyses and the
467 certainty of evidence and encourage evidence users to consider data from preprints in contexts in which
468 decisions are being made rapidly and evidence is being produced faster than can be peer reviewed and
469 published. Skepticism may still be warranted when suspicion arises regarding falsified data (for which we
470 provide criteria).

471 **Tables**

472

Table 1: Trial characteristics								
	All trials n (%) N=356	Published trials without preprints n (%) N=181	Trials only available as preprints n (%) N=101	% difference between trials only available as preprints and published trials without preprints (95% CIs)	P value	Trials first posted as preprints and subsequently published n (%) N=74	% difference between trials first posted as preprints and subsequently published and published trials without preprints (95% CIs)	P value
Trial registered								
Yes	319 (89.6%)	149 (82.3%)	97 (96.0%)	13.72% (7.0 to 20.5)	<0.001	73 (98.6%)	16.3% (10.2 to 22.5)	<0.001
No	37 (10.4%)	32 (17.7%)	4 (4.0%)	-13.72% (-20.5 to -7.0)	<0.001	1 (1.4%)	-16.3% (-22.5 to -10.2)	<0.001
Study status								
Completed	268 (75.3%)	142 (78.5%)	75 (74.3%)	-4.2% (-14.6 to 6.2)	0.44	51 (68.9%)	-9.5% (-21.7 to 2.6)	0.12
Interim results	20 (5.6%)	5 (2.8%)	10 (9.9%)	7.1% (0.8 to 13.4)	0.03	5 (6.8%)	4.0% (-2.2 to 10.2)	0.21
Terminated early for benefit	2 (0.6%)	0 (0%)	2 (2.0%)	2.0% (-0.7 to 4.7)	0.15	0 (0%)	0 (0%)	1.00
Terminated early due to feasibility	66 (18.5%)	34 (18.8%)	14 (13.9%)	-4.9% (-13.7 to 3.9)	0.28	18 (24.3%)	5.5% (-5.8 to 16.9)	0.34
Type of treatment								
Drug therapy	293 (82.3%)	157 (86.7%)	77 (76.2%)	-10.5% (-20.2 to -0.8)	0.03	59 (79.7%)	-7.0% (-17.4 to 3.4)	0.19
Prophylaxis	17 (4.8%)	7 (3.9%)	8 (7.9%)	4.0% (-1.9 to 10.0)	0.18	2 (2.7%)	-1.2% (-5.8 to 3.5)	0.64
Antiviral antibodies and cellular therapies	46 (12.9%)	17 (9.4%)	16 (15.8%)	6.5% (-1.8 to 14.7)	0.13	13 (17.6%)	8.2% (-1.5 to 17.8)	0.10
Inpatient†	252 (74.3%)	129 (72.3%)	65 (69.9%)	-4.3% (-15.6 to 7.1)	0.47	58 (80.6%)	6.4% (-4.8 to 17.6)	0.27
Severe/critical disease†	88 (26.0%)	46 (26.4%)	26 (28.0%)	1.5% (-9.7 to 12.8)	0.80	16 (22.2%)	-4.2% (-15.8 to 7.4)	0.49
Number of centers								
Single center	151 (42.4%)	86 (47.5%)	39 (38.6%)	-8.9% (-20.9 to 3.1)	0.15	26 (35.1%)	-12.4% (-25.5 to 0.7)	0.06
Multicenter	177 (49.7%)	85 (47.0%)	48 (47.5%)	0.6% (-12.0 to 12.7)	0.93	44 (59.5%)	12.5% (-0.8 to 25.8)	0.07
Median [IQR] number of participants	106 [60 to 266]	101 [60 to 208]	163 [64 to 412]			100 [60 to 249]		
Primary outcome statistically significant	151 (42.4%)	74 (40.9%)	49 (48.5%)	7.6% (-4.5 to 19.7)	0.22	28 (37.8%)	-3.1% (-16.2 to 10.1)	0.66
Any secondary outcome(s) statistically significant	186 (52.2%)	90 (49.7%)	53 (52.5%)	2.8% (-9.4 to 14.9)	0.67	43 (58.1%)	8.4% (-5.0 to 21.8)	0.22
Risk of bias								

High risk of bias due to randomization	122 (34.3%)	67 (37.0%)	34 (33.7%)	-3.4% (-15.0 to 8.2)	0.58	19 (25.7%)	-11.3% (-23.5 to 0.9)	0.07
High risk of bias due to deviations from intended intervention	214 (60.1%)	111 (61.3%)	56 (55.5%)	-5.9% (-17.9 to 6.1)	0.34	47 (63.5%)	2.2% (-10.9 to 15.3)	0.76
High risk of bias due to missing outcome data	19 (5.3%)	11 (6.1%)	5 (5.0%)	-1.1% (-6.6 to 4.4)	0.70	3 (4.1%)	-2.0% (-7.7 to 3.7)	0.50
High risk of bias due to measurement of the outcome	7 (2%)	6 (3.3%)	1 (1.0%)	-2.3% (-5.6 to 0.9)	0.16	0 (0%)	-3.3% (-5.9 to -0.7)	0.01
High risk of bias due to selective reporting	22 (6.2%)	9 (5.0%)	8 (7.9%)	3.0% (-3.2 to 9.1)	0.35	5 (6.8%)	1.8% (-4.8 to 8.3)	0.60
High risk of bias overall	228 (64%)	117 (64.6%)	61 (60.4%)	-4.2% (-16.1 to 7.6)	0.49	50 (67.6%)	2.9% (-9.8 to 15.7)	0.67
Funding*								
Industry	79 (22.2%)	32 (17.7%)	30 (29.7%)	12.0% (1.5 to 22.5)	0.02	17 (23%)	5.3% (-5.8 to 16.4)	0.35
Government	126 (35.4%)	47 (26.0%)	37 (36.6%)	10.7% (-0.7 to 22.0)	0.07	42 (56.8%)	30.8% (17.8 to 43.8)	<0.001
Institution	128 (36.0%)	69 (38.1%)	32 (31.7%)	-6.4% (-17.9 to 5.1)	0.28	27 (36.5%)	-1.6% (-14.7 to 11.4)	0.82
Not-for-profit	51 (14.3%)	24 (13.3%)	12 (11.9%)	-1.4% (-9.4 to 6.6)	0.75	15 (20.3%)	7.0% (-3.4 to 17.4)	0.19
Not reported	23 (6.5%)	12 (6.6%)	10 (9.9%)	3.3% (-3.6 to 10.1)	0.36	1 (1.4%)	-5.3% (-9.8 to -0.8)	0.02
No funding	49 (13.8%)	33 (18.2%)	10 (9.9%)	-8.3% (-16.4 to -0.2)	0.04	6 (8.1%)	-10.1% (-18.5 to -1.7)	0.02

* Trials may be classified in more than one category.

† Estimates only include trials addressing therapy.

Time	Proportion of preprints published (%)	Cumulative proportion published
0 to 2 weeks	3/174 (1.7%)	1.7%
2 weeks to 1 month	5/169 (3.0%)	4.7%
1 month to 2 months	12/162 (7.4%)	12.1%
2 months to 3 months	19/133 (14.3%)	25.7%
3 months to 6 months	27/98 (27.6%)	50.1%
6 months to 1 year	9/42 (21.4%)	65.9%
Median (95% CI) time to publication	5.9 months (5.1 to 10.3)	

475

Table 3: Predictors of time to publication of COVID-19 trial preprints		
	Median days (95% Cis)	P value
Funding		
Industry funding (n=47)	171 (145 to NA)	0.72
No industry funding (n=127)	219 (177 to NA)	
Government funding (n=78)	155 (120 to 192)	0.02
No government funding (n=96)	309 (183 to NA)	
Institutional funding (n=58)	136 (90 to NA)	0.14
No institutional funding (n=116)	192 (166 to NA)	
Not-for-profit funding (n=26)	110 (79 to NA)	0.07
No not-for-profit funding (n=148)	188 (161 to NA)	
Number of centers		
Single center (n=65)	undefined (130 to undefined)	0.13
Multicenter (n=90)	161 (136 to 219)	
Number of participants		
More than median (n=88)	142 (120 to NA)	0.14
Less than median (n=85)	219 (171 to NA)	
Intensity of care		
Inpatient (n=122)	110 (95 to 144)	<0.0001
Outpatient (n=38)	undefined	
Severity		
Mild/moderate (79)	182 (159 to 263)	<0.0001
Severe/Critical (42)	101 (89 to 128)	
Early termination for benefit	NA	NA
Primary outcome statistically significant		
Statistically significant (n=77)	243 (155 to undefined)	0.12
Not statistically significant (n=91)	161 (127 to 219)	
Any secondary outcomes statistically significant		
Statistically significant (n=96)	187 (120 to NA)	0.66
Not statistically significant (n=64)	152 (120 to NA)	
Risk of bias		
Low (n=52)	155 (124 to 187)	0.17
High (n=102)	122 (98 to 161)	

"Drug time"	Excluding unpublished preprints						Including all preprints					
	Number of studies	Number of participants	MA estimate	Risk with standard care /placebo (/1000)	Risk difference (/1000 people)	GRADE	Number of studies	Number of participants	MA estimate	Risk with standard care /placebo (/1000)	Risk difference (/1000 people)	GRADE
Mortality												
Corticosteroids												
1 month	1	6425	0.89 [0.81 to 0.98]	130	14.3 fewer (24.7 fewer to 2.6 fewer)	Moderate due to risk of bias	2	6489	0.89 [0.81 to 0.98]	130	14.3 fewer (24.7 fewer to 2.6 fewer)	Moderate due to risk of bias
3 months	5	7667	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate due to risk of bias	6	7731	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate due to risk of bias
6 months	5	7667	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate due to risk of bias	6	7731	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate due to risk of bias
Current	10	7959	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate due to risk of bias	10	7959	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate due to risk of bias
Remdesivir												
1 month	2	1298	0.79 [0.59 to 1.05]	130	27.3 fewer (53.3 fewer to 6.5 more)	Moderate due to imprecision	2	1298	0.79 [0.59 to 1.05]	130	27.3 fewer (53.3 fewer to 6.5 more)	Moderate due to imprecision
3 months	2	1298	0.79 [0.59 to 1.05]	130	27.3 fewer (53.3 fewer to 6.5 more)	Moderate due to imprecision	2	1298	0.79 [0.59 to 1.05]	130	27.3 fewer (53.3 fewer to 6.5 more)	Moderate due to imprecision
6 months	3	1882	0.78 [0.59 to 1.04]	130	28.6 fewer (53.3 fewer to 5.2 more)	Moderate due to imprecision	4	7333	0.90 [0.83 to 0.97]	130	13 fewer (35.1 fewer to 14.3 more)	Low due to imprecision (x2)
Current	5	7415	0.91 [0.75 to 1.11]	130	11.7 fewer (32.5 fewer to 14.3 more)	Low due to imprecision (x2)	6	8247	0.92 [0.75 to 1.07]	130	10.4 fewer (27.3 fewer to 9.1 more)	Moderate due to imprecision
Lopinavir-ritonavir												
1 month	1	199	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low due to risk of bias, imprecision (x2)	2	250	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low due to risk of bias, imprecision (x2)
3 months	2	250	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low due to risk of bias, imprecision (x2)	2	250	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low due to risk of bias, imprecision (x2)
6 months	2	250	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low due to risk of bias, imprecision (x2)	2	250	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low due to risk of bias, imprecision (x2)
Current	7	9427	1.04 [0.95 to 1.14]	130	5.20 more (6.5 fewer to 18.2 more)	Very low due to risk of bias, imprecision (x2)	7	9427	1.04 [0.95 to 1.14]	130	5.20 more (6.5 fewer to 18.2 more)	Very low due to risk of bias, imprecision (x2)
(Hydroxy)chloroquine (treatment)												
1 month	1	30	NA (0 events)	130	NA	NA NA	1	30	NA (0 events)	130	NA	NA NA
3 months	1	30	NA (0 events)	130	NA	NA NA	2	180	NA (0 events)	130	NA	NA NA
6 months	5	1287	1.16 [0.58 to 2.34]	130	20.8 more (54.6 fewer to 174.2 more)	Very low due to risk of bias, imprecision (x3)	9	6135	1.08 [0.98 to 1.19]	130	10.4 more (2.60 fewer to 24.7 more)	Low due to risk of bias, imprecision
Current	19	10634	1.09 [1.00 to 1.19]	130	11.7 more (0 fewer to 24.7 more)	Low due to risk of bias, imprecision	23	10997	1.07 [0.98 to 1.17]	130	9.10 more (2.60 fewer to 22.1 more)	Low due to risk of bias, imprecision
Ivermectin												
1 month	0	0	NA	130	NA	NA NA	1	180	0.18 [0.00 to 0.55]	130	106.6 fewer (122.2 fewer to 65 fewer)	Very low due to risk of bias, imprecision (x2)
3 months	0	0	NA	130	NA	NA NA	4	517	0.33 [0.00 to 1.17]	130	87.1 fewer (118.3 fewer to 22.1 more)	Very low due to risk of bias, imprecision (x2)
6 months	1	398	0.33 [0.01 to 8.05]	130	87.1 fewer (128.7 fewer to 916.5 more)	Very low due to risk of bias, imprecision (x3)	6	1169	0.34 [0.11 to 1.00]	130	85.8 fewer (115.7 fewer to 0 fewer)	Low due to risk of bias, imprecision
Current	5	1220	0.72 [0.28 to 1.85]	130	36.4 fewer (93.6 fewer to 110.5 more)	Very low due to risk of bias, imprecision (x3)	9	1879	0.51 [0.23 to 1.13]	130	63.7 fewer (100.1 fewer to 16.9 more)	Very low due to risk of bias, imprecision (x2)
IL-6 receptor blockers												
1 month	0	0	NA	130	NA	NA NA	1	97	0.84 [0.46 to 1.51]	130	20.8 fewer (70.2 fewer to 66.3 more)	Very low due to risk of bias, imprecision (x3)
3 months	2	26	0.30 [0.04 to 2.27]	130	91 fewer (124.8 fewer to 165.1 more)	Very low due to risk of bias, imprecision (x2)	4	435	0.88 [0.58 to 1.32]	130	15.6 fewer (54.6 fewer to 41.6 more)	Very low due to risk of bias, imprecision (x3)
6 months	6	1292	0.82 [0.67 to 1.00]	130	23.4 fewer (42.9 fewer to 0 fewer)	Low due to risk of bias, imprecision	7	5408	0.87 [0.80 to 0.94]	130	22.1 fewer (31.2 fewer to 13 fewer)	Moderate due to risk of bias
Current	8	5457	0.87 [0.80 to 0.94]	130	22.1 fewer (31.2 fewer to 13 fewer)	Moderate due to risk of bias	11	6303	0.86 [0.80 to 0.93]	130	22.1 fewer (31.2 fewer to 13 fewer)	Moderate due to risk of bias
Convalescent plasma												
1 month	1	101	0.65 [0.29 to 1.46]	130	45.5 fewer (92.3 fewer to 59.8 more)	Very low due to risk of bias, imprecision (x3)	2	187	0.60 [0.33 to 1.10]	130	52 fewer (87.1 fewer to 13 more)	Very low due to risk of bias, imprecision (x3)
3 months	1	101	0.65 [0.29 to 1.46]	130	45.5 fewer (92.3 fewer to 59.8 more)	Very low due to risk of bias, imprecision (x3)	4	428	0.56 [0.32 to 0.97]	130	57.2 fewer (88.4 fewer to 3.90 fewer)	Very low due to risk of bias, imprecision (x2)
6 months	3	898	0.95 [0.68 to 1.33]	130	6.5 fewer (41.6 fewer to 42.9 more)	Very low due to risk of bias, imprecision (x2)	7	1185	0.83 [0.63 to 1.11]	130	22.1 fewer (48.1 fewer to 14.3 more)	Very low due to risk of bias, imprecision (x2)
Current	9	12962	0.98 [0.92 to 1.05]	130	2.60 fewer (10.4 fewer to 6.5 more)	Moderate due to risk of bias	14	16073	0.98 [0.93 to 1.03]	130	2.60 fewer (9.10 fewer to 3.90 more)	Moderate due to risk of bias
(Hydroxy)chloroquine (prophylaxis)												
1 month	1	744	NA (0 events)	3	NA	NA NA	1	744	NA (0 events)	3	NA	NA NA
3 months	1	744	NA (0 events)	3	NA	NA NA	2	3151	0.73 [0.24 to 2.24]	3	0.8 fewer (2.3 fewer to 3.7 more)	High NA
6 months	4	8569	0.73 [0.24 to 2.24]	3	0.8 fewer (2 fewer to 3.7 more)	High NA	4	8569	0.73 [0.24 to 2.24]	3	0.8 fewer (2 fewer to 3.7 more)	High NA

medRxiv preprint doi: <https://doi.org/10.1101/2022.04.04.22273372>; this version posted April 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Current	4	8569	0.73 [0.24 to 2.24]	3	0.8 fewer (2 fewer to 3.7 more)	High	NA	4	8569	0.73 [0.24 to 2.24]	3	0.8 fewer (2 fewer to 3.7 more)	High	NA
Mechanical Ventilation														
Corticosteroids														
1 month	1	5418	0.75 [0.61 to 0.93]	116	43 fewer (59.24 fewer to 22.12 fewer)	Moderate	due to risk of bias	2	5472	1.01 [0.48 to 2.13]	116	1.2 more (60.3 fewer to 131.1 more)	Very low	due to risk of bias, imprecision (x2)
3 months	5	6324	0.84 [0.74 to 0.95]	116	32.56 fewer (44.16 fewer to 19.8 fewer)	Moderate	due to risk of bias	6	6378	0.85 [0.75 to 0.97]	116	17.4 fewer (29 fewer to 3.5 fewer)	Moderate	due to risk of bias
6 months	5	6324	0.84 [0.74 to 0.95]	116	32.56 fewer (44.16 fewer to 19.8 fewer)	Moderate	due to risk of bias	6	6378	0.85 [0.75 to 0.97]	116	17.4 fewer (29 fewer to 3.5 fewer)	Moderate	due to risk of bias
Current	9	6576	0.88 [0.78 to 0.99]	116	27.92 fewer (39.52 fewer to 15.16 fewer)	Moderate	due to risk of bias	9	6576	0.88 [0.78 to 0.99]	116	13.9 fewer (25.5 fewer to 1.2 fewer)	Moderate	due to risk of bias
Remdesivir														
1 month	2	1001	0.59 [0.44 to 0.79]	116	47.6 fewer (65 fewer to 24.4 fewer)	High	NA	2	1001	0.59 [0.44 to 0.79]	116	47.6 fewer (65 fewer to 24.4 fewer)	High	NA
3 months	2	1001	0.59 [0.44 to 0.79]	116	47.6 fewer (65 fewer to 24.4 fewer)	High	NA	2	1001	0.59 [0.44 to 0.79]	116	47.6 fewer (65 fewer to 24.4 fewer)	High	NA
6 months	3	1585	0.56 [0.42 to 0.74]	116	51 fewer (67.3 fewer to 30.2 fewer)	High	NA	4	6549	0.66 [0.51 to 0.87]	116	39.4 fewer (68.4 fewer to 8.1 more)	Low	due to risk of bias, imprecision
Current	5	6619	0.72 [0.46 to 1.12]	116	32.5 fewer (62.6 fewer to 13.9 more)	Low	due to risk of bias, imprecision	6	7451	0.76 [0.51 to 1.04]	116	27.8 fewer (52.2 fewer to 4.6 more)	Low	due to risk of bias, imprecision
Lopinavir-ritonavir														
1 month	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
3 months	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
6 months	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
Current	5	8474	1.14 [1.02 to 1.26]	116	16.2 more (2.3 fewer to 30.2 more)	Low	due to risk of bias, imprecision	5	8474	1.14 [1.02 to 1.26]	116	16.2 more (2.3 fewer to 30.2 more)	Low	due to risk of bias, imprecision
(Hydroxy)chloroquine (Treatment)														
1 month	2	642	1.14 [0.61 to 2.121]	116	16.2 more (45.2 fewer to 129.9 more)	Very low	due to risk of bias, imprecision (x3)	4	4616	1.15 [0.94 to 1.39]	116	17.4 more (7.0 fewer to 45.2 more)	Low	due to risk of bias, imprecision
3 months	4	4693	1.17 [0.96 to 1.42]	116	19.7 more (4.6 fewer to 46.4 more)	Low	due to risk of bias, imprecision	6	6430	1.15 [0.94 to 1.35]	116	17.4 more (3.5 fewer to 40.6 more)	Low	due to risk of bias, imprecision
6 months	7	6877	1.13 [0.96 to 1.32]	116	15.1 more (4.6 fewer to 37.1 more)	Low	due to risk of bias, imprecision	9	7417	1.11 [0.94 to 1.29]	116	12.8 more (4.6 fewer to 33.6 more)	Low	due to risk of bias, imprecision
Current	12	8053	1.23 [1.05 to 1.46]	116	26.7 more (5.8 more to 53.4 more)	Moderate	due to risk of bias	12	8053	1.23 [1.05 to 1.46]	116	26.7 more (5.8 more to 53.4 more)	Moderate	due to risk of bias
Ivermectin														
1 month	1	45	NA (0 events)	116	NA	NA	NA	2	90	1.52 [0.77 to 2.8]	116	60.3 more (107.9 fewer to 496.5 more)	Very low	due to risk of bias, imprecision (x3)
3 months	1	45	NA (0 events)	116	NA	NA	NA	4	354	0.40 [0.25 to 0.46]	116	69.6 fewer (109 fewer to 169.4 more)	Very low	due to risk of bias, imprecision (x3)
6 months	4	642	0.98 [0.55 to 1.72]	116	2.3 fewer (52.2 fewer to 83.5 more)	Low	due to imprecision (x2)	7	951	0.77 [0.58 to 1.06]	116	26.7 fewer (74.2 fewer to 75.4 more)	Very low	due to imprecision (x3)
Current	8	1464	0.94 [0.58 to 1.53]	116	7.0 fewer (48.7 fewer to 61.5 more)	Low	due to imprecision (x2)	9	1616	0.94 [0.58 to 1.53]	116	7.0 fewer (48.7 fewer to 61.5 more)	Low	due to imprecision (x2)
IL-6 receptor blockers														
1 month	0	0	NA	116	NA	NA	NA	1	273	0.76 [0.53 to 1.09]	116	27.8 fewer (54.5 fewer to 10.4 more)	Low	due to risk of bias, imprecision
3 months	3	495	0.68 [0.43 to 1.09]	116	37.1 fewer (66.1 fewer to 10.4 more)	Low	due to risk of bias, imprecision	5	1145	0.71 [0.55 to 0.93]	116	33.6 fewer (52.2 fewer to 8.1 fewer)	Moderate	due to risk of bias
6 months	7	1826	0.74 [0.63 to 0.86]	116	30.2 fewer (42.9 fewer to 16.2 fewer)	Moderate	due to risk of bias	9	4000	0.82 [0.74 to 0.93]	116	20.9 fewer (31.3 fewer to 8.1 fewer)	Moderate	due to risk of bias
Current	10	4170	0.83 [0.74 to 0.93]	116	19.7 fewer (30.2 fewer to 8.1 fewer)	Moderate	due to risk of bias	12	4560	0.83 [0.74 to 0.92]	116	19.7 fewer (30.2 fewer to 8.1 fewer)	Moderate	due to risk of bias
Convalescent plasma														
1 month	1	464	1.08 [0.59 to 1.99]	116	9.3 more (47.6 fewer to 104.4 more)	Very low	due to risk of bias, imprecision (x2)	3	705	0.83 [0.35 to 1.78]	116	19.7 fewer (70.8 fewer to 90.5 more)	Very low	due to risk of bias, imprecision (x2)
3 months	3	827	1.14 [0.81 to 1.61]	116	16.2 more (22 fewer to 70.8 more)	Very low	due to risk of bias, imprecision (x2)	6	1108	1.04 [0.75 to 1.42]	116	4.6 more (29 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
6 months	4	987	1.11 [0.79 to 1.54]	116	12.8 more (24.4 fewer to 62.6 more)	Very low	due to risk of bias, imprecision (x2)	6	1108	1.04 [0.75 to 1.42]	116	4.6 more (29 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
Current	8	8252	0.98 [0.90 to 1.06]	116	2.3 fewer (11.6 fewer to 7 more)	Moderate	due to risk of bias	9	8333	0.98 [0.90 to 1.05]	116	2.3 fewer (11.6 fewer to 5.8 more)	Moderate	due to risk of bias

medRxiv preprint doi: <https://doi.org/10.1101/2022.04.04.22273372>; this version posted April 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.


476

477


478 **Figures**

479

480 **Figure 1: Differences in results reported between preprints and publications for mortality (A) and**
 481 **mechanical ventilation (B)**



482



483

484

485 References

- 486 1. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in
487 Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. 2020:2020.06.22.20137273.
- 488 2. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in
489 Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020.
- 490 3. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine
491 in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled
492 trial. medRxiv. 2020:2020.07.15.20151852.
- 493 4. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine
494 in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-40.
- 495 5. Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, García CH, et al. Repurposed
496 antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv.
497 2020:2020.10.15.20209817.
- 498 6. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al.
499 Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020.
- 500 7. Maslove DM. Medical Preprints-A Debate Worth Having. Jama. 2018;319(5):443-4.
- 501 8. Lauer MS, Krumholz HM, Topol EJ. Time for a prepublication culture in clinical research? Lancet.
502 2015;386(10012):2447-9.
- 503 9. Carneiro CF, Queiroz VG, Moulin TC, Carvalho CA, Haas CB, Rayêe D, et al. Comparing quality of
504 reporting between preprints and peer-reviewed articles in the biomedical literature. BioRxiv.
505 2019:581892.
- 506 10. Walker R, Rocha da Silva P. Emerging trends in peer review-a survey. Front Neurosci.
507 2015;9:169.
- 508 11. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, et al. Increasing value and
509 reducing waste: addressing inaccessible research. Lancet. 2014;383(9913):257-66.
- 510 12. Franco A, Malhotra N, Simonovits G. Social science. Publication bias in the social sciences:
511 unlocking the file drawer. Science. 2014;345(6203):1502-5.
- 512 13. Schmucker C, Schell LK, Portalupi S, Oeller P, Cabrera L, Bassler D, et al. Extent of non-
513 publication in cohorts of studies approved by research ethics committees or included in trial registries.
514 PLoS One. 2014;9(12):e114023.
- 515 14. Scherer RW, Meerpohl JJ, Pfeifer N, Schmucker C, Schwarzer G, von Elm E. Full publication of
516 results initially presented in abstracts. Cochrane Database Syst Rev. 2018;11(11):Mr000005.
- 517 15. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug
518 Administration: review of publication and presentation. PLoS Med. 2008;5(11):e217; discussion e.
519 16. van Schalkwyk MCI, Hird TR, Maani N, Petticrew M, Gilmore AB. The perils of preprints. Bmj.
520 2020;370:m3111.
- 521 17. Flanagan A, Fontanarosa PB, Bauchner H. Preprints Involving Medical Research-Do the Benefits
522 Outweigh the Challenges? Jama. 2020;324(18):1840-3.
- 523 18. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for
524 covid-19: living systematic review and network meta-analysis. Bmj. 2020;370:m2980.
- 525 19. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. Antibody and
526 cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. Bmj.
527 2021;374:n2231.
- 528 20. Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis against covid-
529 19: living systematic review and network meta-analysis. Bmj. 2021;373:n949.

- 530 21. Marshall IJ, Noel-Storr A, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying
531 Randomized Controlled Trials: An evaluation and practitioner's guide. *Res Synth Methods*.
532 2018;9(4):602-14.
- 533 22. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for
534 assessing risk of bias in randomised trials. *Bmj*. 2019;366:l4898.
- 535 23. Lamontagne F, Agoritsas T, Macdonald H, Leo YS, Diaz J, Agarwal A, et al. A living WHO guideline
536 on drugs for covid-19. *Bmj*. 2020;370:m3379.
- 537 24. Centers for Disease Control and Prevention. COVIDView. A weekly surveillance summary of U.S
538 COVID-19 activity 2020 [Available from: .
- 539 26. ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium). COVID-19
540 Report: 08 June 2020. medRxiv 2020.
- 541 27. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging
542 consensus on rating quality of evidence and strength of recommendations. *Bmj*. 2008;336(7650):924-6.
- 543 28. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group
544 clarifies the construct of certainty of evidence. *J Clin Epidemiol*. 2017;87:4-13.
- 545 29. Vlaar APJ, de Bruin S, Busch M, Timmermans S, van Zeggeren IE, Koning R, et al. Anti-C5a
546 antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19
547 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. *Lancet Rheumatol*.
548 2020;2(12):e764-e73.
- 549 30. Vlaar APJadB, Sanne and Busch, Matthias and Timmermans, Sjoerd and van Zeggeren, Ingeborg
550 E. and Koning, Rutger and ter Horst, Liora and Bulle, Esther B. and van Baarle, Frank E.H.P. and van de
551 Poll, Marcel C.G. and Kemper, E. Marleen and van der Horst, Iwan C.C. and Schultz, Marcus J. and Horn,
552 Janneke and Paulus, Frederique and Bos, Lieuwe D. and Wiersinga, W. Joost and Witzernath, Martin and
553 Rueckinger, Simon and Pilz, Korinna and Brouwer, Matthijs C. and Guo, Ren-Feng and Heunks, Leo and
554 van Paassen, Pieter and Riedemann, Niels. C. and van de Beek, Diederik, Anti-C5a Antibody (IFX-1)
555 Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial. .
- 556 31. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in
557 Hospitalized Patients with COVID-19 – Preliminary Report. medRxiv. 2020:2020.06.22.20137273.
- 558 32. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al.
559 AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim
560 Results of a Phase II/III Multicenter Randomized Clinical Trial. *Clin Infect Dis*. 2021;73(3):531-4.
- 561 33. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al.
562 AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III
563 Multicenter Randomized Clinical Trial. medRxiv. 2020:2020.07.26.20154724.
- 564 34. Elgazzar A, Hany B, Youssef SA, Hany B, Hafez M, Moussa H. Efficacy and Safety of Ivermectin for
565 Treatment and prophylaxis of COVID-19 Pandemic. *Research Square*. 2021.
- 566 35. Brown N. A bug and a dilemma 2021 [Available from: .
- 567 36. Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, et al. Efficacy of
568 favipiravir in COVID-19 treatment: a multi-center randomized study. *Arch Virol*. 2021;166(3):949-54.
- 569 37. Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, et al.
570 Retraction Note to: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
571 *Arch Virol*. 2021:1.
- 572 38. Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H, Ebeid FFS, Sherief AF, et al. Retraction Note:
573 Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised
574 controlled trial. *Sci Rep*. 2021;11(1):18983.
- 575 39. Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H, Ebeid FFS, Sherief AF, et al. Safety and
576 efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled
577 trial. *Sci Rep*. 2021;11(1):7282.

- 578 40. Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, et al. Effects of a Single Dose
579 of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot
580 Clinical Trial in Lebanon. *Viruses*. 2021;13(6).
- 581 41. Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, et al. Retraction: Samaha et
582 al. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2
583 Infected Subjects: A Pilot Clinical Trial in Lebanon. *Viruses* 2021, 13, 989. *Viruses*. 2021;13(11).
- 584 42. Carlisle JB. The analysis of 168 randomised controlled trials to test data integrity. *Anaesthesia*.
585 2012;67(5):521-37.
- 586 43. Carlisle JB. Data fabrication and other reasons for non-random sampling in 5087 randomised,
587 controlled trials in anaesthetic and general medical journals. *Anaesthesia*. 2017;72(8):944-52.
- 588 44. Bordewijk EM, Li W, van Eekelen R, Wang R, Showell M, Mol BW, et al. Methods to assess
589 research misconduct in health-related research: A scoping review. *J Clin Epidemiol*. 2021;136:189-202.
- 590 45. Kirkwood AA, Cox T, Hackshaw A. Application of methods for central statistical monitoring in
591 clinical trials. *Clin Trials*. 2013;10(5):783-806.
- 592 46. van den Bor RM, Vaessen PWJ, Oosterman BJ, Zuithoff NPA, Grobbee DE, Roes KCB. A
593 computationally simple central monitoring procedure, effectively applied to empirical trial data with
594 known fraud. *J Clin Epidemiol*. 2017;87:59-69.
- 595 47. Carlisle JB, Dexter F, Pandit JJ, Shafer SL, Yentis SM. Calculating the probability of random
596 sampling for continuous variables in submitted or published randomised controlled trials. *Anaesthesia*.
597 2015;70(7):848-58.
- 598 48. Oikonomidi T, Boutron I, Pierre O, Cabanac G, Ravaud P, the C-NMAC. Changes in evidence for
599 studies assessing interventions for COVID-19 reported in preprints: meta-research study. *BMC Medicine*.
600 2020;18(1):402.
- 601 49. Bero L, Lawrence R, Leslie L, Chiu K, McDonald S, J Page M, et al. Comparison of preprints and
602 final journal publications from COVID-19 Studies: Discrepancies in results reporting and spin in
603 interpretation. *medRxiv*. 2021:2021.04.12.21255329.
- 604

